Libtayo(r) (cemiplimab) Approved by the European Commission for First line Treatment of Patients with Advanced Non small Cell Lung Cancer with =50% PD L1 Expression

Media coverage

• Title	Libtayo(r) (cemiplimab) Approved by the European Commission for First line Treatment of Patients with Advanced Non small Cell Lung Cancer with =50% PD L1 Expression
  Media name/outlet	Market News Publishing
  Country/Territory	United States
  Date	25/06/21
  Persons	Israel Lowy,

• Title	Libtayo(r) (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
  Media name/outlet	Market News Publishing
  Country/Territory	United States
  Date	25/06/21
  Persons	Israel Lowy,